Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips FREYR Battery (NYSE: FREY ) stock is soaring higher on Thursday thanks to a 31 GWh deal for its low-carbon battery cells. Source: asharkyu / Shutterstock.com Here’s everything investors in FREY stock n...
Gainers: Adagio Therapeutics (NASDAQ:ADGI) +68%, Calliditas Therapeutics (NASDAQ:CALT) +28%, Assertio (NASDAQ:ASRT) +17%, Aptose Biosciences (NASDAQ:APTO) +16%, Arcturus Therapeutics (NASDAQ:ARCT) +15%. Losers: uniQure (NASDAQ:QURE) -25%, Regi...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Evercore ISI analyst Kirk Materne recently weighed in on the tech sector and named three software stocks that are ready for a rebound. Source: Shutterstock According to the analyst, there are underperformers in the ...
Calliditas Therapeutics (NASDAQ:CALT) +38% on FDA approval for kidney disease therapy. Kaixin Auto (NASDAQ:KXIN) +27% on a partnership agreement with Bujia for 10k new energy trucks. Biomerica (NASDAQ:BMRA) +18% preliminary second quarter revenue increase of approxima...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re getting right into the swing of things with a breakdown of the biggest pre-market stock movers for Thursday! Source: Shutterstock We’ve got an FDA update, several agreements...
Calliditas Therapeutics (NASDAQ:CALT) +67%. Recursion Pharmaceuticals (NASDAQ:RXRX) +10%. Verrica Pharmaceuticals (NASDAQ:VRCA) +9%. Qorvo (NASDAQ:QRVO) +6%. Sharecare (NASDAQ:SHCR) +5%. Blue Bird (NASDAQ:BLBD) -10%. Freshworks (NASDAQ:FRSH) -4%. Nutanix (NASDAQ:NTNX) -4%. Cumberland Pharmace...
FDA grants Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy - TARPEYO (budesonide) delayed release capsules is the first and only treatment indicated to reduce proteinuria in adults with primary IgA nephropathy...
Calliditas Therapeutics (NASDAQ:CALT) ADRs have climbed in the post-market after the company announced the FDA approval of TARPEYO (budesonide) to address proteinuria in adults with primary immunoglobulin A nephropathy ((IgAN)). FDA clearance for TARPEYO delayed-release capsules tra...
Calliditas Therapeutics: Interim Report Q3, 2021 A quarter of deal making and regulatory review PR Newswire STOCKHOLM , Nov. 18, 2021 /PRNewswire/ -- "Following on from the positive top line read out of Part A our Phase 3 study, we initiated a structured proc...
Calliditas announces poster presentations at ASN Digital Kidney Week 2021 PR Newswire STOCKHOLM , Nov. 3, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced upcoming presentations concerning N...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatri...
2024-06-30 09:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Calliditas provides setanaxib patent update PR Newswire STOCKHOLM , June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) h...